next announcement and likely content, page-109

Roy, money, yes, from which means remains to be seen. No CR before results, confirmation of advancement or tie-in. If you think this won’t add value to ANP well that’s up to you.

What you quote is old pre approval of mipomersen which is very misleading. Mipomersen is approved and off to market whether you like it or not. This gives commercial validation of ANPs drugs.

Perhaps get up to speed and do some due diligence and stop misleading people or talking your book!

“The efficacy of mipomersen in lowering LDL cholesterol and associated, independent markers of cardiovascular risk is excellent and unquestioned.”

“it is clear that the liver safety concerns have been overblown.”

“Neither of these points change the fact that this drug could offer a commercial validation of ISIS's second generation antisense pipeline and provide meaningful revenues to Isis Pharmaceuticals.”

http://www.biotechduediligence.com/mipomersen-long-term-safety-and-efficacy.html

Those who have been reading these threads from the start are up to speed.

That is the last from you goodbye, Roy.